A drug that is supposed to prevent and treat skin disorders could have some very negative side effects, including a higher risk of developing skin cancer.
The company behind the new drug, a peptide, called MELO-1, is trying to combat the devastating effects of aging.
In one study, it showed that a daily dose of MELOs about the amount of vitamin E is enough to reverse the signs of aging in people in their 80s.
But MELo-1 is not approved for human use.
The study also found that people who took MELOS also had a higher than normal risk of heart disease, type 2 diabetes and stroke.
That is because the drug has a stronger effect on the heart and circulatory system than the drug used in many other treatments.
MELoS is now being tested in human trials to see if it can prevent or slow the progression of certain diseases, such as Alzheimer’s disease and other forms of dementia.”MELO1 is an important and promising treatment for some of the most debilitating and life-threatening conditions in aging,” said Dr. R.K. Thakur, the chief executive officer of the company.
It is still not clear whether the drug will work in all people, and some experts say that even in people who are on MELos, the drugs are not likely to fully reverse the damage.
For instance, people who have already had a heart attack and are now on the drug might not feel as much of an impact from the drug.
But for some, such a change may be enough to help them avoid heart attacks and stroke altogether.
Some of the other side effects of the drug include a reduced immune system and reduced capacity to produce insulin, which is used by the body to control blood sugar levels.
Dr. Thomas M. Brown, a professor of dermatology at the University of Michigan, said that even among people who take MELoses daily, the risk of side effects was still higher than usual.
But that was true for everyone who took the drug daily, Brown said.
Brown said that for the first time, there is evidence that MELOLs can actually slow the progress of certain conditions.
“We have been seeing for decades that when you use an anti-aging drug, the more effective the drug is, the less effective the side effects,” he said.
“But this is the first evidence that it has the potential to slow progression of the disease.”
Brown said he does not expect MELOMO to be approved for use in humans, but that the company is working to develop a clinical trial.
If the drug does work in people, he said, “it is certainly a big deal.”
The company has already begun marketing the drug and expects to introduce it to other countries as soon as this year.